Investor profile

Abingworth Bioventures VI

Abingworth LLP · Multi-Country

Investment focus

Start with the fit.

Abingworth Bioventures VI is a life sciences venture capital fund managed by Abingworth LLP, a London-based investor specialising in biotech and healthcare. The 2012-vintage fund closed in 2014 at USD 375 million and invests across Europe and the US, writing tickets of roughly USD 8-30 million per company. Portfolio companies have included Verona Pharma and Vaxcyte.

AI Connector · MCP

Bring EUACC into your AI.

Choose your AI and follow the walkthrough. Your free EUACC account connects the two.

Illustrated walkthrough

Add EUACC to Claude

In Claude, open Customize, then Connectors.
Click + Add, then Add custom connector.
Name it EUACC, paste the link and click Continue.
Review the detected authentication settings and click Continue. Choose Sign in now, then Register automatically under OAuth client.
Click Add, then sign in with your free EUACC account and approve access.

Connector URLhttps://www.euacc.ai/api/mcp

Works on every Claude plan, including Free (one custom connector). On Team and Enterprise, an Owner adds it.

On a phone, add it at claude.ai in your browser. It then shows up in the Claude app the next time you sign in.

Once connected, try this

Use EUACC to explore “Abingworth bioventures vi” (https://www.euacc.ai/investors/abingworth-bioventures-vi). Help me assess investor fit and prepare questions using the available fund profiles. Cite the available sources and flag missing or outdated information.

Your side of the introduction

Give investors a profile worth opening.

List your startup →